Evidence map›Paper›PMID 39676077›Full record

ReviewNature protocols2025

Precise kilobase-scale genomic insertions in mammalian cells using PASTE.

Christopher W Fell, Cian Schmitt-Ulms, Dario V Tagliaferri, Jonathan S Gootenberg, Omar O Abudayyeh

Abstract readReview
In one paragraph

Review in Nature protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. CRISPR Gene Tagging for Illuminating Endogenous Protein Dynamics.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Gene-sized editing for the therapy of genetic diseases.Functional & integrative genomics · 2026
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christopher W Fell *Harvard Medical School, Harvard University, Boston, MA, USA.ORCID 0000-0001-7343-3702
Cian Schmitt-Ulms *Harvard Medical School, Harvard University, Boston, MA, USA.ORCID 0000-0003-1310-9446
Dario V TagliaferriHarvard Medical School, Harvard University, Boston, MA, USA.
Jonathan S GootenbergHarvard Medical School, Harvard University, Boston, MA, USA. jgootenb@bidmc.harvard.edu.ORCID 0000-0003-2757-2175
Omar O AbudayyehHarvard Medical School, Harvard University, Boston, MA, USA. omar@abudayyeh.science.ORCID 0000-0002-7979-3220

Funding

Discovery and manipulation of transcription factors to restore long term stem cell repopulation in aged bone-marrowR01AG074932 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Omar O Abudayyeh, Jonathan Samuel Gootenberg · 2022 to 2026
$3.3M
Programmable gene integration and cell engineering with CRISPR-directed integrasesR01EB031957 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ABUDAYYEH, OMAR O, GOOTENBERG, JONATHAN SAMUEL · 2021 to 2024
$2.4M
Developing programmable RNA writing tools with the novel RNA-guided RNA-targeting CRISPR effector Cas7-11R01GM148745 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Omar O Abudayyeh, Jonathan Samuel Gootenberg · 2023 to 2026
$1.9M
Systematic discovery, characterization, and design of novel genome editing and delivery tools using a high-throughput metagenomic screening pipelineR21AI149694 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ABUDAYYEH, OMAR O, GOOTENBERG, JONATHAN SAMUEL · 2020 to 2021
$414k
RNA targeting tools with novel specific RNA-guided RNA-targeting CRISPR effectorsR56HG011857 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ABUDAYYEH, OMAR O, GOOTENBERG, JONATHAN SAMUEL · 2021 to 2021
$363k
NHGRI NIH HHS R56 HG011857NIAID NIH HHS R21 AI149694NIA NIH HHS R01 AG074932NIBIB NIH HHS R01 EB031957NIGMS NIH HHS R01 GM148745Simons Foundation FellowshipU.S. Department of Health & Human Services | National Institutes of Health (NIH) R01-EB031957
6 · The paper itself

Abstract

Programmable gene integration technologies are an emerging modality with exciting applications in both basic research and therapeutic development. Programmable addition via site-specific targeting elements (PASTE) is a programmable gene integration approach for precise and efficient programmable integration of large DNA sequences into the genome. PASTE offers improved editing efficiency, purity and programmability compared with previous methods for long insertions into the mammalian genome. By combining the specificity and cargo size capabilities of site-specific integrases with the programmability of prime editing, PASTE can precisely insert cargoes of at least 36 kb with efficiencies of up to 60%. Here we outline best practices for design, execution and analysis of PASTE experiments, with protocols for integration of EGFP at the human NOLC1 and ACTB genomic loci and for readout by next generation sequencing and droplet digital PCR. We provide guidelines for designing and optimizing a custom PASTE experiment for integration of desired payloads at alternative genomic loci, as well as example applications for in-frame protein tagging and multiplexed insertions. To facilitate experimental setup, we include the necessary sequences and plasmids for the delivery of PASTE components to cells via plasmid transfection or in vitro transcribed RNA. Most experiments in this protocol can be performed in as little as 2 weeks, allowing for precise and versatile programmable gene insertion.

Indexed as

Gene EditingGenomicsMutagenesis, InsertionalAnimalsGreen Fluorescent ProteinsHigh-Throughput Nucleotide SequencingHumansPlasmidsenhanced green fluorescent proteinGreen Fluorescent Proteins

Identifiers

PMID39676077
PMCPMC12699430

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.